Co-delivery of doxorubicin and SATB1 shRNA by thermosensitive magnetic cationic liposomes for gastric cancer therapy

PLoS One. 2014 Mar 27;9(3):e92924. doi: 10.1371/journal.pone.0092924. eCollection 2014.

Abstract

In previous a study, we had developed a novel thermosensitive magnetic delivery system based on liposomes. This study aimed to evaluate the efficiency of this system for the co-delivery of both drugs and genes to the same cell and its anti-tumor effects on gastric cancer. Doxorubicin (DOX) and SATB1 shRNA vector were loaded into the co-delivery system, and in vitro DOX thermosensitive release activity, targeted gene silencing efficiency, targeted cellular uptake, in vitro cytotoxicity, as well as in vivo anti-tumor activity were determined. The results showed that this co-delivery system had desirable targeted delivery efficacy, DOX thermosensitive release and SATB1 gene silencing. Moreover, the co-delivery of DOX and SATB1 shRNA exhibited enhanced activity to inhibit gastric cancer cell growth in vitro and in vivo, compared to single delivery. In conclusion, the novel thermosensitive magnetic drug and gene co-delivery system has promising application in combined chemotherapy and gene therapy for gastric cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Line, Tumor
  • Disease Models, Animal
  • Doxorubicin / administration & dosage*
  • Drug Delivery Systems*
  • Drug Liberation
  • Gene Silencing
  • Gene Transfer Techniques
  • Humans
  • Liposomes* / chemistry
  • Male
  • Matrix Attachment Region Binding Proteins / genetics*
  • Particle Size
  • RNA, Small Interfering / administration & dosage*
  • Stomach Neoplasms / genetics*
  • Stomach Neoplasms / pathology
  • Stomach Neoplasms / therapy
  • Thermodynamics
  • Transfection
  • Tumor Burden / drug effects
  • Tumor Burden / genetics
  • Xenograft Model Antitumor Assays

Substances

  • Liposomes
  • Matrix Attachment Region Binding Proteins
  • RNA, Small Interfering
  • SATB1 protein, human
  • Doxorubicin

Grants and funding

This study was supported by the National Natural Science Foundation of China (No. 81172186). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.